{
    "id": "dbpedia_6637_1",
    "rank": 95,
    "data": {
        "url": "https://www.slideserve.com/tracy/chronic-pain-pharmacy-services-otcqb-aphy-investor-presentation-october-2013",
        "read_more_link": "",
        "language": "en",
        "title": "Chronic Pain Pharmacy Services (OTCQB: APHY) Investor Presentation October 2013 PowerPoint Presentation",
        "top_image": "https://cdn1.slideserve.com/1636357/slide1-n.jpg",
        "meta_img": "https://cdn1.slideserve.com/1636357/slide1-n.jpg",
        "images": [
            "https://www.slideserve.com/img/logo.svg",
            "https://cdn1.slideserve.com/1636357/slide1-n.jpg",
            "https://www.slideserve.com/photo/29919.jpeg",
            "https://www.slideserve.com/img/output_cBjjdt.gif",
            "https://cdn0.slideserve.com/225056/part-four-treating-end-of-life-symptoms-dt.jpg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg",
            "https://www.slideserve.com/img/preload-bg.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2014-07-11T00:00:00",
        "summary": "",
        "meta_description": "Chronic Pain Pharmacy Services (OTCQB: APHY) Investor Presentation October 2013. Disclaimer. Safe Harbor Statement Slideshow 1636357 by tracy",
        "meta_lang": "en",
        "meta_favicon": "https://www.slideserve.com/img/favicon.ico",
        "meta_site_name": "SlideServe",
        "canonical_link": "https://www.slideserve.com/tracy/chronic-pain-pharmacy-services-otcqb-aphy-investor-presentation-october-2013",
        "text": "Chronic Pain Pharmacy Services (OTCQB: APHY) Investor Presentation October2013\n\nDisclaimer Safe Harbor Statement This document and other written or oral statements made from time to time may contain forward-looking statement s covered by the Private Securities Litigation Reform Act of 1995. Statements that are not historical in nature and which may be identified by the use of words like “expects,” “assumes,” “projects,” ”anticipates,” “estimates,” “we believe,” “target,” “could be,” and other words of similar meaning, are forward-looking statements. Theses statements are based on managements’ expectations and assumptions and are subject to risks and uncertainties that may cause actual results by the forward-looking statements include: lack of sufficient financing for opening new pharmacies, government regulation and controls, and inability to manage growth. Additional information concerning factors that could cause actual results to differ materially from those projected is contained in the Company’s filing with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information since these statements may no longer be accurate or timely. Use of Material Contained Herein This presentation and the information contained herein are confidential. By your receipt of a copy of this presentation (or your attendance in person), in order to comply with Regulation FD, you agree to hold in strict confidence the existence and contents of this presentation, including without limitation the potential offering. This document is intended for informational purposes to obtain indications of interest only and is not intended, no should it be construed, as a recommendation, investment advice, an offer to sell or buy, as solicitation, or an endorsement by Assured Pharmacy or any of their employees or agents.\n\nExecutive Summary • Assured Pharmacy, Inc. (APHY), a growing provider of pharmacy services to patients and physicians in the treatment of chronic pain. Through its network of pharmacies, the Company predominantly dispenses highly regulated pain medications to sufferers of chronic pain, while stringently adhering to federal and state reporting requirements for both patients and physicians. • Operates 2 stores • First store opened in 2003 • Serving ~4000 patients per month • Employees: 35 • APHY carries an inventory of medications that: • Specifically suited to treat chronic pain patients - Class II narcotics • Have complex interactions with other medications • Generally more expensive • Difficult to manage • Highly regulated and dangerous\n\nInvestment Highlights • Profitable Business Model • Low start-up costs:~ $350K • Achieve profitability at only 75 scripts/day with operating capacity to 300 scripts/day • Long term recurring patient revenue stream • Minimal sensitivity to economic cycles • Proven model through 4 locations with infrastructure to support 25 locations in 5 years • Large Underserved Market • Prescription pain medication is a $30 billion/year market in US • Minimal direct competition throughout US • 75 million Americans with chronic pain and growing • Proven Management with Aligned Interests with Shareholders • Strong infrastructure with scalable core management systems and processes • Management team has over 50 years of combined pharmacy/healthcare industry related experience • Management and directors personally invested over $1M alongside investors\n\nBusiness Overview Our specialty pharmacy services specialize in complex therapy pain management and medication support services for sufferers of chronic pain and other complex health conditions. Products includes: • Fentanyl • Oxycontin • MorphineSulfate • Oxycodone • Opana • Hydrocodone • Comprehensive support, dispensing & distribution, patient care management, data reporting • Partnering with patients, physicians, healthcare payers and pharmaceutical manufacturers • Prescription medications are dispensed at twocurrent locations: • Kansas City, KS • Seattle, WA\n\nPain — the Nation’s #1 Disability • More than 75 million Americans suffer from debilitating chronic pain • 2/3 suffering for more than 5 years and experiencing pain almost 6 days a week* • Causes more disability than cancer and heart disease combined • $30B/year is spent on prescription pain medications in the US • Accounts for approximately 75% of all physician visits • Prescription pain medication is the first line of action for treatment and management • Sufferers are often misunderstood and alienated since it is the “invisible” disease • Many “traditional” retail pharmacies, because of their staffing and risk models, typically are not able to provide suffers of acute and chronic pain with the full prescribed quantity of medication on a consistent basis *Harris Interactive/National Pain Foundation\n\nMarket Needs for Specialized Pain Pharmacies • Pharmacists • Physicians • Regulators\n\nAssured Pharmacy Approach Value Proposition to Patients • A relationship pharmacy - Assured Pharmacy gets to know patients • Convenience through daily pickup of prescriptions direct from physician offices • Multiple delivery options available in addition to patient pick up • Fill customers’ prescriptions from existing inventories and avoid the wait time required in a traditional pharmacy • Privacy, closed door pharmacies with low foot traffic • Complete fulfillments on paid prescriptions and accepts most insurance plans Value Proposition to Physicians • Full service, highly secure alternative to traditional pharmacies • Daily pickup of prescriptions by Assured representatives • Convenient, cost effective and minimizes risk of counterfeit prescriptions • Reduced time • Consuming calls from chain pharmacies confirming prescriptions • Government compliance and risk mitigation • Increased controls due to specialization and pharmacy model design • Customized patient, DEA and drug reports\n\nPharmacy Expansion Strategy Expand to new cities in a very prudent method Evaluate physician demand in targeted expansion cities before any commitment Limits the downside risk • Next: • Denver, CO • Boston, MA It’s All About the Network of Relationships • Future: • Nashville, TN • Omaha, NE • Phoenix, AZ • Raleigh, NC\n\nCustomer Acquisition Strategy Target physicians who have the relationships with the chronic pain sufferer patients Provides visibility and predictable revenue Limits the downside risk\n\nPharmacy Business Model • Pharmacy concept • Closed door pharmacy • Walk in prescriptions are limited • 800 – 1,500 sq. Ft. medical office space in secondary & tertiary locations • Pharmacy layout designed with physician office “look & feel” • First rate security measures • Video, motion, and lock storage systems • Staffing: one pharmacist, up to 3 support personal, 2 sales representatives • Geographical coverage area: (~150 mile radius) • Pharmacy revenue model projected at ~ $9.0 million at full capacity (300 scripts/day)\n\nPharmacy Economics • Low start-up costs: ~$350K • Proven business model • Achieve pharmacy level profitability at only 75 scripts/day • Rapid ROI: model built for 300 scripts/day • Long term recurring patient revenue stream • Minimal sensitivity to overall economic cycles • Model is proven through 2 store locations and replicable throughout the US Target patient has chronic pain or other complex health conditions that require multiple prescriptions each month for the rest of their life\n\nKey Performance Indicators\n\nPharmacy Financial Model\n\nShort Term Growth Plan • Grow organically in existing markets by servicing new customers • The industry has underlying market growth potential attributable to both an increase in drug utilization as well as the general aging population of the United States • For 2013 • Negotiate new trade terms: improve inventory, pricing, costs and turn • Streamline operations in order to target profitability in 1st half 2014 • Continue to expand and refine industry leading compliance program • For 2014 • Reach profitability at Kansas City, KS & Seattle, WA locations • Open two new pharmacies in Boston, MA and Denver, CO • Identify three to five additional pharmacy locations for 2015 opening • Beyond 2013 • Consider future locations in major metropolitan areas in Arizona, Minnesota, Missouri, Tennessee, North Carolina and Texas • Expand national footprint: 25+ pharmacies in 5 years\n\nFinancials **Includes stock based compensation of $550k, $783k and $838k for years ending December 31, 2010, 2011 and 2012 respectively\n\nAnnual Rollout - Three Year Projections\n\nManagement • Robert DelVecchio – CEO • CEO since February 2005, Appointed to the Board of Directors in March 2005 • Previously CEO and President of Brockington Securities, Inc., a FINRA Member Firm • Mike Schneidereit – COO • 15+ year career in IT, Operations & Finance in Pharmacy, Healthcare & Real Estate including Cigna Healthcare and Siemens • Formerly, Director of Specialty Pharmacy and Information Technology of SureHealth • Brett Cormier , CPA– CFO • 19+ year career in Accounting & Finance in Pharmacy, Healthcare, Real Estate and Franchising including Monarch Dental and Pharmerica • Formerly, CFO & Treasurer of Sleep Holdings, Inc., • Michael Mapes – CCO • 30+ year career with U.S. Drug Enforcement Administration primarily in the enforcement and prevention of pharmaceutical diversion • Formerly, Section Chief, Washington D.C., U.S. DEA"
    }
}